Biotech entity
All 1 tracked stories fall under one category: funding. Of the tracked stories, 1 of 1 also mention Charles Darwin, the most common co-covered peer. We currently track 1 Biotech story that mention Robert Boyle, all published on July 23, 2026.
Last mentioned: Jul 23, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: funding. Of the tracked stories, 1 of 1 also mention Charles Darwin, the most common co-covered peer. We currently track 1 Biotech story that mention Robert Boyle, all published on July 23, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Robert Boyle. Shared-story counts are live from our verified record — not editorial picks.
The White House’s proposal to replace institutional grants with $200B in portable fellowships and golden tickets could dramatically reshape biotech R&D. Startups might gain direct access to top-flight researchers, while big pharma could see its steady university pipeline disrupted. For the biopharma sector, the plan is a high-stakes bet on curiosity-driven discovery over managed research.
Robert Boyle is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
